A single pathway for the development of essential hypertension

Cardiology in Review

Volumn 11, Issue 4, 2003, Pages 180-196

  Kanellis, John ^a,e   Nakagawa, Takahiko ^a   Herrera Acosta, Jaime ^b   Schreiner, George F ^c   Rodríguez Iturbe, Bernardo ^d   Johnson, Richard J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c SCIOS INC   (United States)

^d HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^e AUSTIN HEALTH   (Australia)

Author keywords

Arteriolosclerosis; Hypertension; Inflammation; Sympathetic nervous system; Uric acid

Indexed keywords

ARTERIOLOSCLEROSIS; DISEASE COURSE; ESSENTIAL HYPERTENSION; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; KIDNEY ISCHEMIA; PATHOGENESIS; REVIEW; RISK FACTOR;

EID: 0037778769     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CRD.0000077361.00668.14     Document Type: Review

References (168)

1. Mahomed FA: On chronic Bright's disease and it's essential symptoms. Lancet 1879;1:399-401. One of the first descriptions of "primary" and "secondary" hypertension.
2. Weinberger MH, Fineberg NS: Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 1991;18:67-71.
3. Carmelli D, Robinette D, Fabsitz R: Concordance, discordance and prevalence of hypertension in World War II male veteran twins. J Hypertens 1994;12:323-328. Non-genetic factors, including adult weight gain, alcohol consumption, and physical activity, are linked to the development hypertension.
4. Dahl LK, Heine M, Thompson K: Genetic influence of the kidneys on blood pressure. Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ Res 1974;40:94-101.
5. Dahl LK, Heine M: Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975;36:692-696. Hypertension in rats can be transferred by transplanting the kidney from hypertension-prone strains into hypertension-resistant strains. Similarly, hypertension was cured by transplanting the kidney from hypertension resistant strains into hypertension prone strains.
6. Rettig R: Does the kidney play a role in the aetiology of primary hypertension? Evidence from renal transplantation studies in rats and humans. J Hum Hypertens 1993;7:177-180. Results of renal transplantation studies in animals and humans suggest that a genetic defect in the kidney plays a major role in the pathogenesis of primary hypertension.
7. Churchill PC, Churchill MC, Bidani AK: Kidney cross transplants in Dahl salt-ensitive and salt-resistant rats. Am J Physiol 1992;262:H1809-H1817.
8. Curtis JJ, Luke RG, Dustan HP, et al.: Remission of essential hypertension after renal transplantation. N Engl J Med 1983;309:1009-1015. Essential hypertension in human beings is shown to be similar to the hypertension in spontaneously hypertensive rats in that both can be corrected by transplantation of a kidney from a normotensive donor.
9. Guyton AC, Coleman TG, Cowley AV Jr, et al.: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972;52:584-594. Contains Guyton's discussion of renal physiological principles and how this proves there must be a role for the kidney in persistent hypertension.
10. Hall JE, Mizelle HL, Hildebrandt DA, et al.: Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension 1990;15:547-559. Discussion of how renal defects contribute to a resetting of the pressure natriuresis curve in patients with essential hypertension.
11. Lifton RP: Molecular genetics of human blood pressure variation. Science 1996;272:676-680. A review of several gene mutations that confer susceptibility to hypertension. In several of these, the mechanism involves altered renal salt and water homeostasis.
12. Sealey JE, Blumenfeld JD, Bell GM, et al.: On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 1988;6:763-777.
13. Cowley AW Jr, Roman RJ: The role of the kidney in hypertension. JAMA 1996;275:1581-1589. Excellent discussion of the kidney's physiological role in the development of hypertension.
14. Brenner BM, Garcia DL, Anderson S: Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988;1:335-347. Evidence for the hypothesis that a reduced number of nephrons leads to inadequate sodium excretion and salt-sensitive hypertension.
15. Keller G, Zimmer G, Mall G, et al.: Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-108.
16. Johnson RJ, Herrera-Acosta J, Schreiner GF, et al.: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-923. A review of the evidence that the kidney is responsible for the development of salt-sensitive hypertension. Provides a unified hypothesis for the development of hypertension, incorporating theories from older as well as more recent studies.
17. Moritz AR, Oldt MR: Arteriolar Sclerosis in hypertensive and non-hypertensive individuals. Am J Pathol 1937;13:679-728. Extensive documentation of the intrarenal arteriolar disease seen in nearly all hypertensive subjects.
18. Sommers SC, Relman AS, Smithwick RH: Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 1958;34:685-715.
19. Tracy RE: Blood pressure related separately to parenchymal fibrosis and vasculopathy of the kidney. Am J Kidney Dis 1992;20:124-131. In a series of 166 autopsies renal "arterial fibroplasia" correlated more strongly with hypertension than did interstitial fibrosis.
20. Tracy RE: Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996;16:126-133. Review of the data from autopsy studies supporting the view that BP increases with age because of progressive fibroplasia of renal interlobular arteries and arterioles which then leads to escalating renal ischemia.
21. Fahr T: Pathogische Anatomie des Morbus Brightii. In: Henke F, Lubarsch O, eds., Handbuch der Spezielen Pathologischen Anatomie und Hitologie. Berlin: Springer; 1925:368-405. Early description of the possible role of intrarenal disease in the pathogenesis of hypertension.
22. Goldblatt H: The renal origin of hypertension. Physiol Rev 1947;27. Goldblatt's seminal hypothesis linking renal ischemia to hypertension.
23. Goldblatt H, Lynch J, Hanzal R, et al.: Studies on experimental hypertension I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379. Goldblatt's seminal studies using his "one clip" model to induce hypertension in dogs.
24. Perera GA: Hypertensive vascular disease: description and natural history. J Chron Dis 1955;1:33-42.
25. Tracy RE, Mercante DE, Moncada A, et al.: Quantitation of hypertensive nephrosclerosis on an objective rational scale of measure in adults and children. Am J Clin Pathol 1986;85:312-318. Demonstrates a mathematical relationship between blood pressure and renal microvascular abnormalities. This relationship can be used to compute expected BP from measurements of microvascular abnormalities in kidneys obtained at autopsy.
26. Johnson RJ, Rodriguez-Iturbe B, Schreiner GF, et al.: Hypertension: a microvascular and tubulointerstitial disease. J Hypertens 2002;20:S1-S7. A discussion and review of the pathophysiological factors in the kidney underlying hypertension,
27. Johnson RJ, Alpers CE, Yoshimura A, et al.: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-474. Studies examining the multiple renal pathological alterations seen in rats receiving angiotensin II by infusion.
28. Johnson RJ, Gordon KL, Suga S, et al.: Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999;34:151-159. Studies showing how temporary increased activity of the sympathetic nervous system can induce the later development of salt-sensitive hypertension.
29. Julius S, Pascual AV, London R: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971;44:413-418.
30. Julius S, Nesbitt S: Sympathetic overactivity in hypertension. A moving target. Am J Hypertens 1996;9:113S-S120.
31. Mancia G: Bjorn Folkow Award Lecture. The sympathetic nervous system in hypertension J Hypertens 1997;15:1553-1565.
32. Levy R, Hillman C, Stroud W, et al.: Transient hypertension: Its significance in terms of later development of sustained hypertension and cardiovascular renal disease. JAMA 1944;126:829-833.
33. Wilson NV, Meyer BM: Early prediction of hypertension using exercise blood pressure. Prev Med 1981;10:62-68.
34. Zimmerman RS, Frohlich ED: Stress and hypertension. J Hypertens Suppl 1990;8:S103-S107.
35. Bevan AT, Honour AJ, Stott FH: Direct arterial pressure recording in unrestricted man. Clin Sci 1969;36:329-344.
36. Conway J, Boon N, Davies C, et al.: Neural and humoral mechanisms involved in blood pressure variability. J Hypertens 1984;2:203-208.
37. Roman RJ, Cowley AW Jr, Garcia-Estan J, et al.: Pressure-diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension 1988;12:168-176.
38. Myers BD, Deen WM, Brenner BM: Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975;37:101-110.
39. Schmieder RE, Veelken R, Schobel H, et al.: Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol 1997;8:893-900.
40. Ekelund LG, Suchindran CM, Karon JM, et al.: Blackwhite differences in exercise blood pressure. The Lipid Research Clinics Program Prevalence Study. Circulation 1990;81:1568-1574.
41. Dimsdale JE, Graham RM, Ziegler MG, et al.: Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. Hypertension 1987;10:564-569.
42. Campese VM, Parise M, Karubian F, et al.: Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991;18:805-812.
43. Tracy RE, Bhandaru SY, Oalmann MC, et al.: Blood pressure and nephrosclerosis in black and white men and women aged 25 to 54. Mod Pathol 1991;4:602-609.
44. Marcantoni C, Ma LJ, Federspiel C, et al.: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002;62:172-180.
45. Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987;252:F1003-F1010.
46. Kang DH, Hughes J, Mazzali M, et al.: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448-1457. VEGF treatment reduces fibrosis and stabilizes renal function in the remant kidney model, suggesting angiogenic factors may represent a new approach to the treatment of progressive kidney disease.
47. Kang DH, Kanellis J, Hugo C, et al.: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002;13:806-816. A review of the mechanisms underlying microvascular alterations seen in renal disease and the possible therapeutic implications.
48. Timmermann B, Mo R, Luft FC, et al.: Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int 1998;53:1455-1460.
49. Dahl LK, Heine M, Tassinari L: Effects of chronic excess salt ingestion. Vascular reactivity in two strains of rats with oppositie genetic susceptibility to experimental hypertension. Circulation 1964;30:S11-S22.
50. Simchon S, Manger W, Blumberg G, et al.: Impaired renal vasodilation and urinary cGMP excretion in Dahl salt-sensitive rats. Hypertension 1996;27:653-657.
51. Hwang EF, Williams I, Kovacs G, et al.: Impaired ability of the Na+/Ca2+ exchanger from the Dahl/Rapp Salt sensitive rat to regulate cytosolic calcium. Am J Physiol Renal Physiol 2003, in press.
52. Jaffe D, Sutherland LE, Barker DM, et al.: Effects of chronic excess salt ingestion. Morphologic findings in kidneys of rats with differing genetic susceptibilities to hypertension. Arch Pathol 1970;90:1-16.
53. Johnson RJ, Gordon KL, Giachelli C, et al.: Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens 2000;18:1497-1505. Tubulointerstitial injury and the loss of nitric oxide synthase occur after birth and parallel the development of hypertension in the Dahl salt-sensitive rat.
54. Sanders PW: Salt-sensitive hypertension: lessons from animal models. Am J Kidney Dis 1996;28:775-782. Provides an overview of the role of nitric oxide in the pathogenesis of salt-sensitive hypertension.
55. Brezis M, Rosen S, Silva P, et al.: Selective vulnerability of the medullary thick ascending limb to anoxia in the isolated perfused rat kidney. J Clin Invest 1984;73:182-190.
56. Fine LG, Orphanides C, Norman JT: Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int 1998;65:S74-S78.
57. Franco M, Tapia E, Santamaria J, et al.: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 2001;12:2263-2271. Studies showing a role for renal cortical vasoconstriction (induced by angiotensin II infusion) in salt-sensitive hypertension in rats. Mycophenolate mofetil prevented the development of salt-sensitive hypertension, suggesting an important role for the immune system in its pathogenesis.
58. Lombardi D, Gordon KL, Polinsky P, et al.: Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension 1999;33:1013-1019. Angiotensin II infusion in rats induces a renal microvascular disease. This leads to the later development of salt-sensitive hypertension.
59. Andoh TF, Johnson RJ, Lam T, et al.: Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. Am J Transplant 2001;1:222-227.
60. Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106. Renal injury and hypertension in this mild hyperuricemia model are reduced by enalapril or L-arginine, implicating the renin-angiotensin and nitric oxide systems in the pathophysiology.
61. Mazzali M, Kanellis J, Han L, et al.: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997. Hydrochlorothiazide did not prevent mild hyperuricemia or arteriolopathy despite controlling blood pressure, whereas arteriolopathy and hypertension were prevented by both enalapril and losartan.
62. Langford HG: Dietary potassium and hypertension: epidemiologic data. Ann Intern Med 1983;98:770-772.
63. Linas SL, Dickmann D: Mechanism of the decreased renal blood flow in the potassium-depleted conscious rat. Kidney Int 1982;21:757-764.
64. Suga SI, Phillips MI, Ray PE, et al.: Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. Am J Physiol Renal Physiol 2001;281:F620-F629. Hypokalemia is associated with alterations in vasoactive mediators that favor intrarenal vasoconstriction and an ischemic pattern of renal injury.
65. Suga S, Yasui N, Yoshihara F, et al.: Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. J Am Soc Nephrol 2003;14:397-406.
66. Suga S, Mazzali M, Ray PE, et al.: Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. Kidney Int 2002;61:951-958.
67. Ray PE, Suga S, Liu XH, et al.: Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. Kidney Int 2001;59:1850-1858. This study shows that potassium deficiency can increase blood pressure in rats and induce salt sensitivity.
68. Miyamoto Y, Saito Y, Kajiyama N, et al.: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998;32:3-8.
69. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.
70. Norrelund H, Christensen KL, Samani NJ, et al.: Early narrowed afferent arteriole is a contributor to the development of hypertension. Hypertension 1994;24:301-308. In spontaneously hypertensive rats afferent arteriolar narrowing contributes to later development of hypertension.
71. Bergstrom G, Johansson I, Stevenson KM, et al.: Perindopril treatment affects both preglomerular renal vascular lumen dimensions and in vivo responsiveness to vasoconstrictors in spontaneously hypertensive rats. Hypertension 1998;31:1007-1013.
72. Imig JD, Falck JR, Gebremedhin D, et al.: Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension 1993;22:357-364.
73. Wu XW, Muzny DM, Lee CC, et al.: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.
74. Cannon PJ, Stason WB, Demartini FE, et al.: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-464.
75. Selby JV, Friedman GD, Quesenberry CP Jr: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990;131:1017-1027.
76. Jossa F, Farinaro E, Panico S, et al.: Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994;8:677-681.
77. Kahn HA, Medalie JH, Neufeld HN, et al.: The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 1972;84:171-182.
78. Goldstein HS, Manowitz P: Relation between serum uric acid and blood pressure in adolescents. Annals Hum Biol 1993;20:423-431.
79. Klein R, Klein BE, Cornoni JC, et al.: Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973;132:401-410.
80. Nakagawa T, Mazzali M, Kang DH, et al.: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2002;23:2-7.
81. Kanellis J, Kang DH, Nakagawa T, et al.: The regulation of inflammatory mediators by uric acid in vitro and in vivo, suggests a role for hyperuricemia in the pathogenesis of vascular disease. J Am Soc Nephrol 2002;13:60A, abstract.
82. Watanabe S, Kang DH, Feng L, et al.: Uric Acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-360.
83. Kang DH, Nakagawa T, Feng L, et al.: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
84. Brand FN, McGee DL, Kannel WB, et al.: Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985;121:11-18.
85. Kannel WB: Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114:413-419.
86. Hochberg MC, Thomas J, Thomas DJ, et al.: Racial differences in the incidence of gout. The role of hypertension Arthritis Rheum 1995;38:628-632.
87. Martinez FJ, Sancho-Rof JM: Epidemiology of high blood pressure and obesity. Drugs 1993;46(Suppl 2):160-164.
88. Schafer H, Pauleit D, Sudhop T, et al.: Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 2002;122:829-839.
89. Jefferson JA, Escudero E, Hurtado ME, et al.: Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia. Am J Kidney Dis 2002;39:1135-1142.
90. Faller J, Fox IH: Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982;307:1598-1602.
91. Sanchez-Fructuoso AI, Torralbo A, Arroyo M, et al.: Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transplant 1996;11:1775-1780.
92. Ferris TF, Gorden P: Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 1968;44:359-365.
93. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al.: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002;283:F1105-F1110.
94. Mazzali M, Jefferson A, Ni Z, et al.: Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 2003, in press.
95. Vaziri ND, Wang ZQ: Sustained systemic arterial hypertension induced by extended hypobaric hypoxia. Kidney Int 1996;49:1457-1463.
96. Lesske J, Fletcher EC, Bao G, et al.: Hypertension caused by chronic intermittent hypoxia-influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:1593-1603.
97. Masilamani S, Zhang XZ, Baylis C: Blunted pressure natriuretic response in the old rat: participation of the renal nerves. Am J Kidney Dis 1998;32:605-610.
98. Kang DH, Anderson S, Kim YG, et al.: Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001;37:601-611.
99. Ferder LF, Inserra F, Basso N: Advances in our understanding of aging: role of the renin-angiotensin system. Curr Opin Pharmacol 2002;2:189-194.
100. Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Interstitial inflammation, sodium retention, and the pathogenesis of nephrotic edema: a unifying hypothesis. Kidney Int 2002;62:1379-1384.
101. Alvarez V, Quiroz Y, Nava M, et al.: Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002;283:F1132-F1141.
102. Wilson C, Byrom FB: The vicious cycle in chronic Bright's disease: experimental evidence from the hypertensive rat. QJM 1941;10:65-93. Early evidence that renal structural alterations induced by transient hypertension can then be the cause of longer term hypertension.
103. Eng E, Veniant M, Floege J, et al.: Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994;7:177-185. Studies showing how the temporary exposure of a kidney to high blood pressure can lead to significant inflammation and chronic tubulointerstitial injury.
104. Rodriguez-Iturbe B, Pons H, Quiroz Y, et al.: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001;59:2222-2232. Mycophenolate mofetil reduces renal infiltration and activation of immune cells in an angiotensin II infusion model of hypertension.
105. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, et al.: Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 2001;59:1626-1640. A review of the role of the immune system in various renal diseases, the associated pathophysiological factors involved and potential treatment strategies.
106. Wilcox CS, Welch WJ, Murad F, et al.: Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proceedings of the National Academy of Sciences of the United States of America 1992;89:11993-11997. Data showing a role for nitric oxide in volume and BP homeostasis, in addition to its ability to modulate vascular tone.
107. Vaziri ND, Wang XQ, Oveisi F, et al.: Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000;36:142-146.
108. Mattson DL, Bellehumeur TG: Neural nitric oxide synthase in the renal medulla and blood pressure regulation. Hypertension 1996;28:297-303. Studies demonstrating a role for neuronal nitric oxide synthase (nNOS) in the long-term control of blood pressure in the presence of a high salt diet.
109. Lombardi DM, Viswanathan M, Vio CP, et al.: Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron 2001;87:66-74.
110. Winternitz SR, Katholi RE, Oparil S: Decrease in hypothalamic norepinephrine content following renal denervation in the one-kidney, one clip Goldblatt hypertensive rat. Hypertension 1982;4:369-373.
111. DiBona GF: Renal neural mechanisms in salt-sensitive hypertension. Blood Press Suppl 1995;2:81-87.
112. Ye S, Nosrati S, Campese VM: Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997;99:540-548.
113. Denton KM, Shweta A, Anderson WP: Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 2002;13:27-34.
114. Quiroz Y, Pons H, Gordon KL, et al.: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001;281:F38-47. Mycophenolate mofetil prevented the development of salt sensitive hypertension in this rat model and resulted in less segmental glomerulosclerosis, less infiltrating T cells, lower angiotensin II expression, and less thickening of afferent arterioles.
115. Rodriguez-Iturbe B, Quiroz Y, Nava M, et al.: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002;282:F191-F201. The effective treatment of hypertension with mycophenolate mofetil (an immunosuppressive agent) in an animal model.
116. Kang DH, Kim YG, Andoh TF, et al.: Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 2001;280:F727-F736. Treatment of animals with established cyclosporine nephropathy with VEGF reduces the hypertensive response and accelerates histological recovery.
117. Beretta-Piccoli C, Davies DL, Boddy K, et al.: Relation of arterial pressure with body sodium, body potassium and plasma potassium in essential hypertension. Clin Sci (Lond) 1982;63:257-270.
118. Beretta-Piccoli C, Weidmann P: Circulatory volume in essential hypertension. Relationships with age, blood pressure, exchangeable sodium, renin, aldosterone and catecholamines. Miner Electrolyte Metab 1984;10:292-300.
119. Lebel M, Grose JH, Blais R: Abnormal relation of extracellular fluid volume and exchangeable sodium with systemic arterial pressure in early borderline essential hypertension. Am J Cardiol 1984;54:1267-1271.
120. London GM, Levenson JA, London AM, et al.: Systemic compliance, renal hemodynamics, and sodium excretion in hypertension. Kidney Int 1984;26:342-350.
121. Gruskin AB: The adolescent with essential hypertension. Am J Kidney Dis 1985;6:86-90.
122. Saito I, Saruta T, Kondo K, et al.: Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 1978;26:241-247.
123. DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997;77:75-197.
124. Vaamonde CA, Sporn N, Lancestremer RG, et al.: Augmented natriuretic response to acute sodium infusion after blood pressure elevation with metaraminol in normotensive subjects. J Clin Invest 1964;43:496-502.
125. Williams GH, Hollenberg NK: 'Sodium-sensitive' essential hypertension. Emerging insights into pathogenesis and therapeutic implications Contemp Nephrol 1985;3303-311.
126. Lowenstein J, Beranbaum ER, Chasis H, et al.: Intrarenal pressure and exaggerated natriuresis in essential hypertension. Clin Sci 1970;38:359-374.
127. Granger JP: Pressure natriuresis: Role of renal interstitial hydrostatic pressure. Hypertension 1992;19:I9-I17.
128. Romero JC, Knox FG: Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension 1988;11:724-738.
129. Papper S, Belsky JL, Bleifer KH: Response to administration of an isotonic sodium chloride-lactate solution in patients with essential hypertension. J Clin Invest 1960;39:876-884.
130. Carmines PK, Bell PD, Roman RJ, et al.: Prostaglandins in the sodium excretory response to altered renal arterial pressure in dogs. Am J Physiol 1985;248:F8-F14.
131. Majid DS, Navar LG: Nitric oxide in the mediation of pressure natriuresis. Clin Exp Pharmacol Physiol 1997;24:595-599.
132. Wang CT, Chin SY, Navar LG: Impairment of pressure-natriuresis and renal autoregulation in ANG II-infused hypertensive rats. Am J Physiol Renal Physiol 2000;279: F319-F325.
133. Gomez-Alamillo C, Sanchez-Casajus A, Sierra M, et al.: Vasoconstriction of the afferent arteriole and defective renal synthesis of nitric oxide in essential hypertension. Kidney Int Suppl 1996;55:S129-S131.
134. Sanai T, Kimura G: Renal function reserve and sodium sensitivity in essential hypertension. J Lab Clin Med 1996;128:89-97.
135. Kurokawa K: Kidney, salt, and hypertension: how and why. Kidney Int Suppl 1996;55:S46-S51.
136. Bhan RD, Giacomelli F, Wiener J: Adrenoreceptor blockade in angiotensin-induced hypertension: effect on rat coronary arteries and myocardium. Am J Pathol 1982;108:60-71.
137. Blaustein MP, Hamlyn JM: Pathogenesis of essential hypertension. A link between dietary salt and high blood pressure. Hypertension 1991;18:III184-III195.
138. de Wardener HE: The primary role of the kidney and salt intake in the aetiology of essential hypertension: Part II. Clin Sci (Lond) 1990;79:289-297.
139. de Wardener HE: The primary role of the kidney and salt intake in the aetiology of essential hypertension: Part I. Clin Sci (Lond) 1990;79:193-200.
140. Morris HR, Etienne AT, Panico M, et al.: Hypothalamic hypertensive factor: an inhibitor of nitric oxide synthase activity. Hypertension 1997;30:1493-1498.
141. Omvik P, Tarazi RC, Bravo EL: Regulation of sodium balance in hypertension. Hypertension 1980;2:515-523.
142. Hall JE, Guyton AC, Brands MW: Pressure-volume regulation in hypertension. Kidney Int 1996;55:S35-S41.
143. Kimura G, Brenner BM: A method for distinguishing salt-sensitive from non-salt-sensitive forms of human and experimental hypertension. Curr Opin Nephrol Hypertens 1993;2:341-349.
144. Bianchi S, Bigazzi R, Baldari G, et al.: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994;7:23-29.
145. Uzu T, Kazembe FS, Ishikawa K, et al.: High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 1996;28:139-142.
146. Middeke M, Schrader J: Nocturnal blood pressure in normotensive subjects and those with white coat, primary, and secondary hypertension. BMJ 1994;308:630-632.
147. Pickering TG: Blood pressure measurement and detection of hypertension. Lancet 1994;344:31-35.
148. Julius S, Schork MA: Predictors of hypertension. Ann N Y Acad Sci 1978;304:38-58.
149. Luke RG: Essential hypertension: a renal disease? A review and update of the evidence. Hypertension 1993;21:380-390.
150. Tracy RE: The heterogeneity of vascular findings in the kidneys of patients with benign essential hypertension. Nephrol Dial Transplant 1999;14:1634-1639.
151. Bohle A, Ratschek M: The compensated and the decompensated form of benign nephrosclerosis. Pathol Res Pract 1982;174:357-367.
152. Gaedeke J, Peters H, Noble NA, et al.: Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001:153-160.
153. Blake GJ, Ridker PM: Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med 2000;1:161-165.
154. Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
155. Vogel RA, Corretti MC, Plotnick GD: Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37-40.
156. Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-2064.
157. Selzman CH, Miller SA, Zimmerman MA, et al.: Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol 2002;283:H1455-H1461.
158. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
159. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286.
160. Bataillard A, Vincent M, Sassard J, et al.: Antihypertensive effect of an immunosuppressive agent, cyclophosphamide, in genetically hypertensive rats of the Lyon strain. Int J Immunopharmacol 1989;11:377-384.
161. Ba D, Takeichi N, Kodama T, et al.: Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. J Immunol 1982;128:1211-1216.
162. Khraibi AA, Smith TL, Hutchins PM, et al.: Thymectomy delays the development of hypertension in Okamoto spontaneously hypertensive rats. J Hypertens 1987;5:537-541.
163. Nava M, Quiroz Y, Vaziri ND, et al.: Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003;284:F447-F454.
164. Rodriguez-Iturbe B, Zhan D-E, Quiroz Y, et al.: Antioxidant-rich diet improves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 2003;41:341-346.
165. London GM, Safar ME, Sassard JE, et al.: Renal and systemic hemodynamics in sustained essential hypertension. Hypertension 1984;6:743-754.
166. Luke RG: Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol 1991;2:S37-S44.
167. Vio CP, Olavarria V, Gonzalez C, et al.: Cellular and functional aspects of the renal kallikrein system in health and disease. Biol Res 1998;31:305-322.
168. Muirhead EE: Renal vasodepresor mechanisms: the medullipin system. J Hypertens 1193;11(Suppl 5):S53-S58.